GW Pharmaceuticals (United Kingdom)

Institution (Company)

Homepage Wikipedia ROR

Also Known As

GW Pharmaceuticals (United Kingdom)

613

Publications

191.7K

Citations

119

Authors

394

Concepts

About

GW Pharmaceuticals (United Kingdom) is a company institution in Cambridge, United Kingdom known for medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	16	34	5.2K
2	Engineering	14	21	1.5K
3	Arts	1	1	24
4	Business	1	1	17
5	Education	1	2	148

GW Pharmaceuticals (United Kingdom)

613

Publications

191.7K

Citations

Page 1

	Year	Citations
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Hannah Farmer, Nuala McCabe, Christopher J. Lord, Nature Genome InstabilityDna DamageBrca Mutant CellsMedicineMolecular Biology	2005	6.5K
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers Peter C.C. Fong, David S. Boss, Timothy A. Yap, New England Journal of Medicine	2009	3.6K
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome Orrin Devinsky, J. Helen Cross, Linda Laux, New England Journal of Medicine	2017	1.6K
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Cancer Research	2006	1.3K
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks Ali Jazayeri, Jacob Falck, Claudia Lukas, Nature Cell Biology ChromatinGenome InstabilityTranscriptional RegulationDna DamageCell Division	2005	1K
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome Orrin Devinsky, Anup D. Patel, J. Helen Cross, New England Journal of Medicine	2018	948
Effects of cannabinoids and cannabinoid‐enriched <i>Cannabis</i> extracts on TRP channels and endocannabinoid metabolic enzymes Luciano De Petrocellis, Alessia Ligresti, Aniello Schiano Moriello, British Journal of Pharmacology	2010	903
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial Elizabeth A. Thiele, Eric D. Marsh, Jacqueline A. French, The Lancet Placebo-controlled Phase 3NeuropharmacologyPharmacotherapyNeurologyMedicine	2018	868
A Pathway of Double-Strand Break Rejoining Dependent upon ATM, Artemis, and Proteins Locating to γ-H2AX Foci Enriqueta Riballo, Martin Kühne, Nicole Rief, Molecular Cell Genome InstabilityTranscriptional RegulationProtein FunctionNatural SciencesGenetics	2004	826
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity Christine M. Chresta, Barry R. Davies, Ian Hickson, Cancer Research Mtorc2 Substrate AktCell DeathPharmacotherapyTumor BiologyMtorc1 Substrates	2009	790

Page 1